Latest filings (excl ownership)
15-12G
Securities registration termination
21 Aug 23
EFFECT
Notice of effectiveness
16 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
POS AM
Prospectus update (post-effective amendment)
11 Aug 23
8-K
Completion of Acquisition or Disposition of Assets
11 Aug 23
25-NSE
Exchange delisting
11 Aug 23
SC TO-T/A
Third party tender offer statement (amended)
10 Aug 23
SC 14D9/A
Tender offer solicitation (amended)
10 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
SC TO-T/A
Third party tender offer statement (amended)
1 Aug 23
SC 14D9/A
Tender offer solicitation (amended)
1 Aug 23
SC TO-T/A
Third party tender offer statement (amended)
18 Jul 23
SC 14D9/A
Tender offer solicitation (amended)
18 Jul 23
SC 14D9
Tender offer solicitation
13 Jul 23
SC TO-T
Third party tender offer statement
13 Jul 23
8-K
Lilly to Acquire Sigilon Therapeutics
29 Jun 23
SC TO-C
Information about tender offer
29 Jun 23
8-K
Termination of a Material Definitive Agreement
22 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
9 May 23
ARS
2022 FY
Annual report to shareholders
6 Apr 23
DEFA14A
Additional proxy soliciting materials
6 Apr 23
DEF 14A
Definitive proxy
6 Apr 23
PRE 14A
Preliminary proxy
23 Mar 23
S-8
Registration of securities for employees
14 Mar 23
10-K
2022 FY
Annual report
14 Mar 23
8-K
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
14 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Other Events
28 Feb 23
8-K
Departure of Directors or Certain Officers
13 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
10 Nov 22
8-K
Regulation FD Disclosure
11 Oct 22
8-K
Departure of Directors or Certain Officers
26 Sep 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
4 Aug 22
Latest ownership filings
SC 13G/A
Flagship Ventures Fund V, L.P.
14 Feb 24
4
NOUBAR AFEYAN
15 Aug 23
SC 13D/A
ELI LILLY & Co
14 Aug 23
4
Change in insider ownership
14 Aug 23
4
Douglas G. Cole
11 Aug 23
4
Stephen N. Oesterle
11 Aug 23
4
Eric D. Shaff
11 Aug 23
4
ROBERT R RUFFOLO
11 Aug 23
4
John Cox
11 Aug 23
4
Matthew Paul Kowalsky
11 Aug 23
4
Kavita Patel
11 Aug 23
4
Philip Ashton-Rickardt
11 Aug 23
4
Qing Sarah Yuan
11 Aug 23
4
Coelho Rogerio Vivaldi
11 Aug 23
4
Josias Pontes
11 Aug 23
4
Qing Sarah Yuan
27 Jul 23
4
Josias Pontes
24 Jul 23
4
Coelho Rogerio Vivaldi
24 Jul 23
SC 13D
ELI LILLY & Co
7 Jul 23
3
Initial statement of insider ownership
7 Jul 23
4
ROBERT R RUFFOLO
22 May 23
4
Kavita Patel
22 May 23
4
Stephen N. Oesterle
22 May 23
4
John Cox
22 May 23
4
Eric D. Shaff
22 May 23
4
Douglas G. Cole
22 May 23
4
Matthew Paul Kowalsky
1 Mar 23
4
Coelho Rogerio Vivaldi
1 Mar 23
4
Josias Pontes
1 Mar 23
4
Philip Ashton-Rickardt
1 Mar 23
4
Qing Sarah Yuan
1 Mar 23
3
Matthew Paul Kowalsky
1 Mar 23
SC 13G
BlackRock Inc.
8 Jul 22
4
Eric D. Shaff
27 May 22
4
Kavita Patel
27 May 22
4
Stephen N. Oesterle
27 May 22
4
ROBERT R RUFFOLO
27 May 22
4
Douglas G. Cole
27 May 22
4
Brooke Story
27 May 22
4
John Cox
27 May 22